ARISTOCORT
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARISTOCORT is an oral tablet small molecule approved in 1957 by Astellas with unknown mechanism of action and therapeutic indications. The drug's exact clinical profile cannot be fully characterized due to missing pharmacological and indication data. This legacy product represents a mature asset in the modern pharmaceutical portfolio.
LOE Approaching
Legacy asset with low current commercial momentum and likely declining team investment as loss of exclusivity approaches.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ARISTOCORT currently shows zero linked job openings, reflecting its status as a legacy asset with minimal active hiring. Working on this product offers stability and regulatory expertise but limited career advancement and commercial growth opportunity.
Brand ManagerProduct Manager
Worked on ARISTOCORT at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.